Shanghai Henlius Biotech Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China

Reuters

09/30

<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China

**Shanghai Henlius Biotech Receives Regulatory Approval for New Cancer Clinical Trial** Shanghai Henlius Biotech Inc. announced that its application to conduct a Phase 1b/2 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanised monoclonal antibody injection) has been approved by China's National Medical Products Administration. The trial will focus on the treatment of advanced or metastatic solid tumours. Recent results from the phase 1 clinical trial, presented at the 2025 World Conference on Lung Cancer, showed promising efficacy and safety in patients with advanced solid tumours, particularly non-small cell lung cancer. The approval is specific to Shanghai Henlius Biotech Inc., with no indication of grant or funding involvement from other organizations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571348601"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571348601\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571348601?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 17:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571348601","market":"us","top_or_hot":-1,"title":"Shanghai Henlius Biotech Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a> Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Shanghai Henlius Biotech Receives Regulatory Approval for New Cancer Clinical Trial** Shanghai Henlius Biotech Inc. announced that its application to conduct a Phase 1b/2 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanised monoclonal antibody injection) has been approved by China's National Medical Products Administration. The trial will focus on the treatment of advanced or metastatic solid tumours. Recent results from the phase 1 clinical trial, presented at the 2025 World Conference on Lung Cancer, showed promising efficacy and safety in patients with advanced solid tumours, particularly non-small cell lung cancer. The approval is specific to Shanghai Henlius Biotech Inc., with no indication of grant or funding involvement from other organizations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Henlius Biotech Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Henlius Biotech Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-30 17:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a> Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Shanghai Henlius Biotech Receives Regulatory Approval for New Cancer Clinical Trial** Shanghai Henlius Biotech Inc. announced that its application to conduct a Phase 1b/2 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanised monoclonal antibody injection) has been approved by China's National Medical Products Administration. The trial will focus on the treatment of advanced or metastatic solid tumours. Recent results from the phase 1 clinical trial, presented at the 2025 World Conference on Lung Cancer, showed promising efficacy and safety in patients with advanced solid tumours, particularly non-small cell lung cancer. The approval is specific to Shanghai Henlius Biotech Inc., with no indication of grant or funding involvement from other organizations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00656","symbol_name":"復星國際","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL2SyM5f:1","article_id":"2571348601","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571348601","pubTimestamp":1759224705,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shanghai Henlius Biotech Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China. **Shanghai Henlius Biotech Receives Regulatory Approval for New Cancer Clinical Trial** Shanghai Henlius Biotech Inc. announced that its application to conduct a Phase 1b/2 clinical trial of HLX43 for injection  in combination with HLX07  has been approved by China's National Medical Products Administration. The trial will focus on the treatment of advanced or metastatic solid tumours. Recent results from the phase 1 clinical trial, presented at the 2025 World Conference on Lung Cancer, showed promising efficacy and safety in patients with advanced solid tumours, particularly non-small cell lung cancer. The approval is specific to Shanghai Henlius Biotech Inc., with no indication of grant or funding involvement from other organizations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00656":"复星国际","BK1161":"生物科技","02696":"复宏汉霖","BK1230":"工业集团企业"},"translate_title":"复宏汉霖生物获监管部门批准在中国开始HLX43联合疗法治疗晚期实体瘤的1b/2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00656":0.9,"02696":0.9},"content_text":"Shanghai Henlius Biotech Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China\n    \n\n        **Shanghai Henlius Biotech Receives Regulatory Approval for New Cancer Clinical Trial** Shanghai Henlius Biotech Inc. announced that its application to conduct a Phase 1b/2 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanised monoclonal antibody injection) has been approved by China's National Medical Products Administration. The trial will focus on the treatment of advanced or metastatic solid tumours. Recent results from the phase 1 clinical trial, presented at the 2025 World Conference on Lung Cancer, showed promising efficacy and safety in patients with advanced solid tumours, particularly non-small cell lung cancer. The approval is specific to Shanghai Henlius Biotech Inc., with no indication of grant or funding involvement from other organizations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}